ReViral has raised $55 million (€47 million) to put a treatment for respiratory syncytial virus (RSV) infections through midphase trials. The series B round comes six months after ReViral completed a ...
Cyrano Therapeutics is savoring a phase 2 victory. With the Flavor study hitting its primary endpoint, the biotech is preparing to take its treatment for persistent smell loss into phase 3 in the ...
Investors have bought into MediPrint Ophthalmics’ vision for drug delivery contact lenses. With a phase 2b of its lead glaucoma asset looming into view, MediPrint has pulled together a series A to ...
Visus Therapeutics is coming for AbbVie. After ceding a big head start to AbbVie’s recently approved Vuity, Visus has posted midphase data that advance its effort to come from behind in the new market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results